|
KMID : 1188320140080050557
|
|
Gut and Liver
2014 Volume.8 No. 5 p.557 ~ p.562
|
|
|
Validation of Group B Borderline Resectable Pancreatic Cancer: Retrospective Analysis
|
|
Oh Tak-Geun
Chung Moon-Jae
Bang Seung-Min
Park Seung-Woo
Chung Jae-Bok
Song Si-Young
Seong Jin-Sil
Kang Chang-Moo
Lee Woo-Jung
Park Jeong-Youp
|
|
|
Abstract
|
|
|
Background/Aims:Among borderline resectable pancreatic cancer (BRPC), group B BRPC patients have findings that are suggestive but not diagnostic of metastasis. In this study, we attempted to validate whether group B could truly be categorized as a borderline resectable group.
Methods:We placed the BRPC patients into group A or group B. The survival outcomes were compared between the groups.
Results:A total of 53 patients with pancreatic adenocarcinoma was classified as either group A or B borderline resectable. In group A, 23 (60.5%) of 38 patients underwent pancreatectomy after concurrent chemoradiotherapy or chemotherapy, but in group B, only five (33.3%) of 15 patients underwent pancreatectomy, mainly because of the progression of suspected distant metastasis. There was a significant difference in overall survival (OS) between group A and B patients (median OS, 21.2 months vs 10.2 months, respectively; p=0.007). Of the patients who underwent pancreatectomy, group B had a higher recurrence rate compared to group A (recurrence rate: 11 of 23 patients [47.8%] vs five of five patients [100%], respectively; p=0.033).
Conclusions:This report is the first to validate the definition of BPRC. Group B had much worse outcomes, and whether group B BRPC can be categorized as BRPC together with group A is questionable.
|
|
|
KEYWORD
|
|
|
Pancreatic neoplasms, Chemoradiotherapy, Chemotherapy, Prognosis
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|
|